CN105055981A - Medicine for treating postpartum persistent lochia caused by blood stasis - Google Patents
Medicine for treating postpartum persistent lochia caused by blood stasis Download PDFInfo
- Publication number
- CN105055981A CN105055981A CN201510601590.8A CN201510601590A CN105055981A CN 105055981 A CN105055981 A CN 105055981A CN 201510601590 A CN201510601590 A CN 201510601590A CN 105055981 A CN105055981 A CN 105055981A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- blood stasis
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating postpartum persistent lochia caused by blood stasis. The medicine is prepared from the following materials in parts by weight: 1-10 parts of assorted Chinese herbal tea, 1-10 parts of circium japonicum, 10-20 parts of pittosporm roots, 10-20 parts of Chinese alpine rush, 1-10 parts of rubia cordifolia, 1-10 parts of tangerine pith, 15-30 parts of sporobolus fertilis, 10-20 parts of antenoron roots, 1-10 parts of white muscardine silkworm, 1-10 parts of euonymus porphyreus, 5-15 parts of panax japonicas, 1-10 parts of radix cyathulae, 10-20 parts of bifurcate cinquefoil herb, 1-10 parts of resina liquidamberis, 10-20 parts of kwangtung beautyberry stems and leaves, 10-20 parts of bermudagrass, 5-15 parts of lycopus lucidus, 1-10 parts of persimmon bark, 1-10 parts of pollen typhae roots, 10-20 parts of camellia oleifera leaves, 1-10 parts of liquorice and 10-20 parts of ginkgo roots. The medicine provided by the invention is capable of activating blood circulation to dissipate blood stasis, cooling blood and removing stagnation as main functions, and benefiting qi, nourishing blood, clearing away heat and toxic materials and nourishing the kidneys and ying as secondary functions, and is significant in treatment effect on postpartum persistent lochia caused by blood stasis and worthy of clinical popularization.
Description
The divisional application of the patent of " a kind of medicament for the treatment of blood stasis type lochia non-stop in puerperal " that the present invention is application number is 201510068052.7, the applying date, to be February 10, denomination of invention in 2015 be.
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of blood stasis type lochia non-stop in puerperal.
Background technology
The turbid liquid of blood of having a surplus puerperal is discharged from uterus by vagina, is called " lochia ".Normally " lochia " starts as color, in dim red or scarlet, after then gradually light amount is few, without foul smell.Generally clean at about 3 weeks.If lochia continues more than 20 days still dripping unclean persons, be called puerperal " lochia non-stop ".Lochia non-stop is one of department of obstetrics and gynecology commonly encountered diseases, frequently-occurring disease.Although vaginal hemorrhage amount is few, dripping clean, if delay with the passing of time, deficient qi and blood, resistance reduction easily causes the diseases such as puerperal infection, seriously affects the physical and mental health of puerpera, then necessary prevention and therapy in time.According to statistics, China has more than 2,000 ten thousand puerperas every year, in the process of clear-cutting forestland in puerperal, about has the women of 70% to there is the symptom of the different lochia non-stop of degree.External report is on the rise also known as this phenomenon.Therefore significant to the treatment of primary disease.
Primary disease is called subinvolution of uterus by modern medicine, in treatment except the symptomatic treatment measures such as antiinflammatory, short uterine contraction hemostasis, the clearing heat in the pericardium, does not have remarkable effective method.And in the treatment of primary disease, Chinese medicine has unique advantage, can be the misery that most of patients avoids the clearing heat in the pericardium, and Chinese medicine has no side effect, do not affect suckling, patient is more acceptant.After Zhang Zhongjing it " golden plaque outline " in Han dynasty proposes, through ancient Chinese medicine doctor to the research of primary disease and discussion, gradually perfect to its understanding.Current Chinese medicine thinks this pathogenetic mechanism, and mainly punching is appointed for sick, and caused by QI-blood circulation is not normal, commonly encountered diseases is because having three: the stasis of blood, void, heat, namely stops in blood stasis, fresh blood must not return through; Body void adds deficiency of vital energy blood damage in puerperal more usually, and the deficiency of vital energy can not take the photograph blood; Heat in blood internal resistance, the absurd row of forcing blood.Wherein stopping in blood stasis is direct, the main factor producing lochia non-stop, also common clinically.Therefore, the Chinese drugs agentia developing efficient, safe treatment blood stasis type in puerperal lochia non-stop is necessary.
Summary of the invention
The object of this invention is to provide a kind of medicament for the treatment of blood stasis type lochia non-stop in puerperal.
In order to realize object of the present invention, the invention provides a kind of medicament for the treatment of blood stasis type lochia non-stop in puerperal, it is made up of the material of following weight portion: assorted Chinese medicine tea 1-10 part, Radix Cirsii Japonici 1-10 part, pittosporm root 10-20 part, Chinese alpine rush 10-20 part, Radix Rubiae 1-10 part, Vascular aurantii 1-10 part, Herba sporoboli purpureasuffusi 15-30 part, Radix Antenoronis Filiformis 10-20 part, Bombyx Batryticatus 1-10 part, pale reddish brown winged euonymus 1-10 part, Rhizoma Panacis Japonici 5-15 part, Radix Cyathulae 1-10 part, Herba Potentillae Bifurcae 10-20 part, Resina Liquidambaris 1-10 part, Caulis Seu Folium Callicarpae Kwangtungensis 10-20 part, Bermuda grass 10-20 part, Herba Lycopi 5-15 part, Cortex Kaki 1-10 part, Rhizoma typhae 1-10 part, Camellia Leaves 10-20 part, Radix Glycyrrhizae 1-10 part, Radix Ginkgo 10-20 part.
Preferably, the medicament for the treatment of blood stasis type lochia non-stop in puerperal of the present invention is made up of the material of following weight portion: assorted Chinese medicine tea 8 parts, Radix Cirsii Japonici 6 parts, pittosporm root 12 parts, Chinese alpine rush 12 parts, 8 parts, Radix Rubiae, Vascular aurantii 6 parts, Herba sporoboli purpureasuffusi 20 parts, Radix Antenoronis Filiformis 15 parts, Bombyx Batryticatus 6 parts, pale reddish brown winged euonymus 8 parts, Rhizoma Panacis Japonici 9 parts, Radix Cyathulae 8 parts, Herba Potentillae Bifurcae 12 parts, Resina Liquidambaris 5 parts, Caulis Seu Folium Callicarpae Kwangtungensis 12 parts, Bermuda grass 15 parts, Herba Lycopi 10 parts, Cortex Kaki 10 parts of, Rhizoma typhae 8 parts, Camellia Leaves 12 parts, 9 parts, Radix Glycyrrhizae, Radix Ginkgo 15 parts.
More preferably, described medicament can be tablet, dispersible tablet, capsule, soft capsule or decoction.
The present invention also provides the purposes of compositions in the medicament of preparation treatment blood stasis type lochia non-stop in puerperal, described compositions is made up of the material of following weight portion: assorted Chinese medicine tea 1-10 part, Radix Cirsii Japonici 1-10 part, pittosporm root 10-20 part, Chinese alpine rush 10-20 part, Radix Rubiae 1-10 part, Vascular aurantii 1-10 part, Herba sporoboli purpureasuffusi 15-30 part, Radix Antenoronis Filiformis 10-20 part, Bombyx Batryticatus 1-10 part, pale reddish brown winged euonymus 1-10 part, Rhizoma Panacis Japonici 5-15 part, Radix Cyathulae 1-10 part, Herba Potentillae Bifurcae 10-20 part, Resina Liquidambaris 1-10 part, Caulis Seu Folium Callicarpae Kwangtungensis 10-20 part, Bermuda grass 10-20 part, Herba Lycopi 5-15 part, Cortex Kaki 1-10 part, Rhizoma typhae 1-10 part, Camellia Leaves 10-20 part, Radix Glycyrrhizae 1-10 part, Radix Ginkgo 10-20 part.
Preferably, described compositions is made up of the material of following weight portion: assorted Chinese medicine tea 8 parts, Radix Cirsii Japonici 6 parts, pittosporm root 12 parts, Chinese alpine rush 12 parts, 8 parts, Radix Rubiae, Vascular aurantii 6 parts, Herba sporoboli purpureasuffusi 20 parts, Radix Antenoronis Filiformis 15 parts, Bombyx Batryticatus 6 parts, pale reddish brown winged euonymus 8 parts, Rhizoma Panacis Japonici 9 parts, Radix Cyathulae 8 parts, Herba Potentillae Bifurcae 12 parts, Resina Liquidambaris 5 parts, Caulis Seu Folium Callicarpae Kwangtungensis 12 parts, Bermuda grass 15 parts, Herba Lycopi 10 parts, Cortex Kaki 10 parts of, Rhizoma typhae 8 parts, Camellia Leaves 12 parts, 9 parts, Radix Glycyrrhizae, Radix Ginkgo 15 parts.
More preferably, described medicament can be tablet, dispersible tablet, capsule, soft capsule or decoction.
In the present compositions, Resina Liquidambaris, Herba Lycopi, pale reddish brown winged euonymus are monarch drug; Assorted Chinese medicine tea, Radix Cirsii Japonici, pittosporm root, Chinese alpine rush, Radix Rubiae, Vascular aurantii are ministerial drug; Herba sporoboli purpureasuffusi, Radix Antenoronis Filiformis, Bombyx Batryticatus, Rhizoma Panacis Japonici, Radix Cyathulae, Herba Potentillae Bifurcae, Caulis Seu Folium Callicarpae Kwangtungensis, Bermuda grass, Cortex Kaki, Rhizoma typhae, Camellia Leaves, Radix Ginkgo are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.
Medicament of the present invention is that inventor established in conjunction with self facing disease experience.Wherein each material synergism, complement each other, play the merit of monarch altogether, capable stagnant based on promoting blood circulation to remove blood stasis, removing heat from blood, be aided with QI invigorating and blood producing, heat-clearing and toxic substances removing, nourishing kidney-YIN, treatment blood stasis type lochia non-stop Be very effective in puerperal, clinic is promoted.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take assorted Chinese medicine tea 80 grams, Radix Cirsii Japonici 60 grams, pittosporm root 120 grams, Chinese alpine rush 120 grams, 80 grams, Radix Rubiae, Vascular aurantii 60 grams, Herba sporoboli purpureasuffusi 200 grams, Radix Antenoronis Filiformis 150 grams, Bombyx Batryticatus 60 grams, pale reddish brown winged euonymus 80 grams, Rhizoma Panacis Japonici 90 grams, Radix Cyathulae 80 grams, Herba Potentillae Bifurcae 120 grams, Resina Liquidambaris 50 grams, Caulis Seu Folium Callicarpae Kwangtungensis 120 grams, Bermuda grass 150 grams, Herba Lycopi 100 grams, Cortex Kaki 100 grams of, Rhizoma typhae 80 grams, Camellia Leaves 120 grams, 90 grams, Radix Glycyrrhizae, Radix Ginkgo 150 grams, add 60000 ml waters, reflux 3 hours in the flask that condensing tube is housed, then filter, obtain filtrate 1 and filtering residue 1; 2) in filtering residue 1, add 20000 ml waters, reflux 1 hour in the flask that condensing tube is housed, filter, obtain filtrate 2 and filtering residue 2; 3) merge described filtrate 1, filtrate 2, be cooled to room temperature, obtain final product.
The therapeutic effect of experimental example 1 decoction of the present invention
1, physical data
This group patient is totally 80 examples.With reference to the Standards of Chinese Medical Syndrome Differentiation in the 6th edition " Gynecology of Chinese Medicine ", all patients all belong to the situation of blood stasis type lochia non-stop in puerperal, and not concurrent pelvic infection, caused by non-hysteromyoma or tumor, the disturbances of blood coagulation such as platelet-free minimizing, absent cardiovascular, liver, kidney and hemopoietic system severe primary disease or psychosis.
80 routine patients are divided into treatment group 50 example and matched group 30 example at random.Wherein the treatment group age is between 20 ~ 39 years old, 30.6 years old mean age; The longest 62 days, the shortest 23 days to natural law of bleeding when observing, natural law of on average bleeding is 47.3 days; Vaginal delivery 19 example, Cesarean esction 31 example.The matched group age between 21 ~ 42 years old, 31.4 years old mean age; The longest 70 days, the shortest 21 days to natural law of bleeding when observing, natural law of on average bleeding is 49.5 days; Vaginal delivery 8 example, Cesarean esction 22 example.
Before treatment, calculate the TCM syndrome evaluation of two groups of patients according to table 1 below:
Table 1 TCM syndrome evaluation table
Through calculating, average 14.62 ± 4.86 points for the treatment of group, average 13.94 ± 4.51 points of matched group.Through t check analysis, the age of two groups of patients and TCM syndrome evaluation there are no significant difference (p>0.05).
2, method
Treatment group takes decoction of the present invention prepared by embodiment above, every day twice, clinical drug dosage be 5.96g crude drug/day/people.Matched group takes Herba Leonuri granule electuary (being produced by Lingfeng Pharmaceutical Co., Ltd., Guangxi), each one bag (every bag of 15g), every day three times.Two groups of equal continuous uses of patient 7 days are a course for the treatment of.
3, evaluation index
(1) clinical evaluation index
Formulate with reference to " Chinese medical disease Standardization of diagnosis and curative effect ".
Recovery from illness: 3 days per vaginam stopped bleeding of taking medicine, clinical symptom disappearance;
Effective: the hemorrhage minimizing of per vaginam in 3 days of taking medicine (more originally reducing more than 2/3), clinical symptom relief;
Take a turn for the better: the hemorrhage minimizing of per vaginam in 6 days of taking medicine (more originally reducing more than 2/3), clinical symptom relief;
Invalid: 6 days hemorrhage nothings of per vaginam of taking medicine obviously reduce, and clinical symptoms is without improvement.
(2) tcm syndrome evaluation index
Again carry out symptom score according to table 1, and calculate therapeutic index (N) and effective percentage according to twice score value.
Recovery from illness: N >=90%; Effective: N=70%-89%; Take a turn for the better: N=30%-69%; Invalid: N < 30%.Wherein:
Score value × 100% before therapeutic index (N)=(before treatment the rear score value of score value-treatment)/treatment
Effective percentage=(cure+effective+take a turn for the better) number of cases/total number of cases × 100%
4, statistical method adopts SPSS17.0 statistical software to carry out data analysis.Measurement data with
represent, adopt t inspection; Enumeration data adopts x
2inspection.With p≤0.05 for difference has statistical significance.
5, result
Clinical efficacy after two groups of patient treatments is in table 2.
Table 2 Clinical efficacy comparison
Note: compare with matched group, * p<0.05
Table 2 shows, and the clinical efficacy of two groups has significant difference (p<0.05).This shows that treatment group symptom takes a turn for the better and is better than matched group, and the clinical efficacy of medicament of the present invention is better than Herba Leonuri granule electuary.
Before and after two groups of patient treatments, TCM syndrome evaluation is in table 3, and curative effect is in table 4.
Table 3 TCM syndrome evaluation compares
Note: compare with before treatment, * p<0.05; Compare with after treatment of control group, * p<0.05
As shown in Table 3, the scoring after two groups of patient treatments comparatively before treatment all has significant difference, and after treatment two groups of patients scoring group between compare and have significant difference.
Table 4 tcm syndrome comparitive study
Note: compare with matched group, * p<0.05
As can be seen from Table 4, the tcm syndrome curative effect of two groups has significant difference.This shows that the tcm syndrome curative effect of medicament of the present invention is better than Herba Leonuri granule electuary.
Experimental example 2 toxicity test
Acute toxicity test: application NIH mice 60, SPF level, male and female half and half, body weight 17 ~ 24g, carries out acute toxicity test.Mice is divided into two groups at random, often organizes 30, i.e. matched group and administration group, fasting 12 hours before experiment; The decoction prepared in adjustment embodiment, concentration is made to be 5.34g crude drug/ml, gavage, gavage volume is 5ml/kg (namely single gives pharmaceutical quantities is 26.7g crude drug/kg), matched group gives normal saline, administration in a day 2 times, delivery time 6 hours, Continuous Observation 14 days after administration, and record toxic reaction and the death toll of mice.Experimental result shows: compare with matched group, and after administration, mice has no notable difference, and experiment Continuous Observation 14 days, mouse systemic situation, diet, drinking-water, body weight increase all normal.Select to put to death administration group mice, test under microscope: the important organs such as the heart, liver, lung, gastric and thymus, no abnormality seen changes.Mouse oral gavage decoction LD of the present invention
50>26.7g crude drug/kg, every day, maximum dosage-feeding was 53.4g crude drug/kg/ day.Clinical drug dosage of the present invention be 5.96g crude drug/day/people, adult body weight in 60kg, average dosage is 0.099g crude drug/kg/ day.By weighing machine: the dosis tolerata of mice (average weight is in 21g) oral administration gavage Chinese medicine of the present invention is 539 times of quantity.Therefore the medicament acute toxicity that takes orally of the present invention is low, clinical drug safety.
Long term toxicity test: application SD rat, body weight 200g ± 10g, male and female half and half.The decoction prepared in embodiment is used to test.Prepare high, medium and low three dosage groups, be respectively 300,150,75 times of clinical application amount, mix with the normal saline 1:1 containing 2 % by weight Radix Acaciae senegalis.Adopt gastric infusion mode, continuous use 16 weeks (1.0ml/100g body weight, every day 2 times) and drug withdrawal after 4 weeks, result shows: the index such as hair, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat of medicine of the present invention to rat all has no significant effect, internal organs naked eyes do not find that difference change and histological indications show, medication 16 weeks and drug withdrawal are after 4 weeks, and each internal organs of rat are all without obviously changing.Illustrate that the medicament that the present invention is taken orally is little to toxicity after rat long-term prescription, also there is no difference reaction after drug withdrawal, application safety.
Claims (3)
1. the purposes of compositions in the medicament of preparation treatment blood stasis type lochia non-stop in puerperal, wherein said compositions is made up of the material of following weight portion: assorted Chinese medicine tea 1-10 part, Radix Cirsii Japonici 1-10 part, pittosporm root 10-20 part, Chinese alpine rush 10-20 part, Radix Rubiae 1-10 part, Vascular aurantii 1-10 part, Herba sporoboli purpureasuffusi 15-30 part, Radix Antenoronis Filiformis 10-20 part, Bombyx Batryticatus 1-10 part, pale reddish brown winged euonymus 1-10 part, Rhizoma Panacis Japonici 5-15 part, Radix Cyathulae 1-10 part, Herba Potentillae Bifurcae 10-20 part, Resina Liquidambaris 1-10 part, Caulis Seu Folium Callicarpae Kwangtungensis 10-20 part, Bermuda grass 10-20 part, Herba Lycopi 5-15 part, Cortex Kaki 1-10 part, Rhizoma typhae 1-10 part, Camellia Leaves 10-20 part, Radix Glycyrrhizae 1-10 part, Radix Ginkgo 10-20 part.
2. purposes according to claim 1, wherein said compositions is made up of the material of following weight portion: assorted Chinese medicine tea 8 parts, Radix Cirsii Japonici 6 parts, pittosporm root 12 parts, Chinese alpine rush 12 parts, 8 parts, Radix Rubiae, Vascular aurantii 6 parts, Herba sporoboli purpureasuffusi 20 parts, Radix Antenoronis Filiformis 15 parts, Bombyx Batryticatus 6 parts, pale reddish brown winged euonymus 8 parts, Rhizoma Panacis Japonici 9 parts, Radix Cyathulae 8 parts, Herba Potentillae Bifurcae 12 parts, Resina Liquidambaris 5 parts, Caulis Seu Folium Callicarpae Kwangtungensis 12 parts, Bermuda grass 15 parts, Herba Lycopi 10 parts, Cortex Kaki 10 parts of, Rhizoma typhae 8 parts, Camellia Leaves 12 parts, 9 parts, Radix Glycyrrhizae, Radix Ginkgo 15 parts.
3. purposes according to claim 1 and 2, wherein said medicament can be tablet, dispersible tablet, capsule, soft capsule or decoction.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510068052.7A CN104606554A (en) | 2015-02-10 | 2015-02-10 | Agentia for treating blood-stasis type non-stop lochia after delivery |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510068052.7A Division CN104606554A (en) | 2015-02-10 | 2015-02-10 | Agentia for treating blood-stasis type non-stop lochia after delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055981A true CN105055981A (en) | 2015-11-18 |
Family
ID=53141375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510601590.8A Pending CN105055981A (en) | 2015-02-10 | 2015-02-10 | Medicine for treating postpartum persistent lochia caused by blood stasis |
| CN201510068052.7A Pending CN104606554A (en) | 2015-02-10 | 2015-02-10 | Agentia for treating blood-stasis type non-stop lochia after delivery |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510068052.7A Pending CN104606554A (en) | 2015-02-10 | 2015-02-10 | Agentia for treating blood-stasis type non-stop lochia after delivery |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105055981A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998069A (en) * | 2015-08-31 | 2015-10-28 | 济南舜昊生物科技有限公司 | Medicine for treating postpartum lochiorrhea blood stasis syndrome and preparing method of medicine |
| CN105169295A (en) * | 2015-11-02 | 2015-12-23 | 程志娟 | Traditional Chinese medicine pills for treating puerperal uterine subinvolution and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813876A (en) * | 2012-07-28 | 2012-12-12 | 陈双玲 | Traditional Chinese medicine for treating postpartum lochiorrhea by activating blood and removing blood stasis |
| CN103251886A (en) * | 2013-04-27 | 2013-08-21 | 李淑丽 | Chinese medicine for treating postpartum lochiorrhea and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103041328A (en) * | 2012-12-17 | 2013-04-17 | 青岛盛瀚色谱技术有限公司 | Traditional Chinese medicine composition for treating blood stasis type lochiorrhea |
-
2015
- 2015-02-10 CN CN201510601590.8A patent/CN105055981A/en active Pending
- 2015-02-10 CN CN201510068052.7A patent/CN104606554A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813876A (en) * | 2012-07-28 | 2012-12-12 | 陈双玲 | Traditional Chinese medicine for treating postpartum lochiorrhea by activating blood and removing blood stasis |
| CN103251886A (en) * | 2013-04-27 | 2013-08-21 | 李淑丽 | Chinese medicine for treating postpartum lochiorrhea and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 侯敏等: "祛瘀汤治疗产后恶露不绝132例", 《陕西中医》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104606554A (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784933A (en) | Recurrent oral ulcer power | |
| CN104338078A (en) | Pharmaceutical composition for treating intrahepatic cholestasis in gestation period | |
| CN105055981A (en) | Medicine for treating postpartum persistent lochia caused by blood stasis | |
| CN101433586B (en) | Medicament for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN104257800A (en) | Medicament for treating acnes | |
| CN104147544A (en) | Traditional Chinese medicinal composition for treating chronic anal cryptitis | |
| WO2002092109A1 (en) | Herbal composition and its use | |
| CN102579677A (en) | Chinese medicinal composition for treating brain glioma | |
| CN104587389A (en) | Traditional Chinese medicine composition for treating neck shoulder pain and lumbocrural pain | |
| CN104547105A (en) | Agent for reducing blood glucose | |
| CN104524315A (en) | Pharmaceutical composition for treating threatened abortion | |
| CN109793826A (en) | A kind of Chinese medicine composition for treating fracture of children | |
| CN103800822A (en) | Traditional Chinese medicinal composition for treating hypertensive cerebral hemorrhage | |
| CN115040576B (en) | Pharmaceutical composition for treating acute pancreatitis | |
| CN114949147B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method and application thereof | |
| CN112546190B (en) | Traditional Chinese medicine composition for treating myelodysplastic syndrome, preparation method and application thereof, and honeyed pills | |
| CN110302271B (en) | Cape jasmine capable of dispelling cold and preparation method thereof | |
| CN106038812A (en) | Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN104523854A (en) | Pharmaceutical composition for treating post-abortion menstrual disorder | |
| CN104474513A (en) | Medicine for treating endometriosis | |
| CN104398827A (en) | Medicament for treating bronchial asthma | |
| CN104491077A (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN105287954A (en) | Traditional Chinese medicine composition for treating qi-stagnation and blood stasis type postpartum abdominal pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151118 |